Arrhythmias & electrophysiologyCohort study
Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence
- Prospective cohort study with genetic association analysis
- UK Biobank
- multivariable Cox regression
- polygenic score
- Follow-up 3.56, 0.47-8.92 years
Authors' conclusion
Our findings suggest that FGF23 is a potential biomarker for accessing AF-related outcomes.
Study context
- Population
- Atrial fibrillation (AF) patients with follow-up data, UK Biobank886 with serum FGF23 analysis
- Participants
- 35,197 patients
- Exposure
- Serum FGF23 and genetically predicted FGF23 vs AF-related outcomes
- Outcome
- AF-related outcomes: mortality, HF, ischaemic stroke, dementia
Main finding
As reported in the abstract
Serum FGF23 (per SD) and AF-related outcomes
All-cause mortality, increase in risk per SD of serum FGF23
37%
CV mortality, increase in risk per SD of serum FGF23
40%
Heart failure (HF), increase in risk per SD of serum FGF23
43%
Observational data: associations, not effects.
Further findings
Genetic association: PGSFGF23 (7 SNPs) and outcomes after first AF diagnosis
- Increased PGSFGF23 associated with reduced risk of HF but increased risk of all-cause mortality and ischaemic stroke
Original publication
Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence. Eur J Prev Cardiol. Published 29 January 2025. doi:10.1093/eurjpc/zwaf001
Summarised from the published abstract; every number is checked against it